Vaccination with Hsp70-peptide complexes isolated from tumor cells can elicit CD8+ T cell specific antitumor immune responses (40, 41), membrane-bound Hsp70 serves as a tumor-specific target for Hsp70-activated natural killer (NK) cells (42–45), and circulating Hsp70 can act as a biomarker for monitoring outcome in patients with head and neck cancer (46). Here, CD8A is linked to neoplasm.